Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on modern management of frailty

LIVE: Thursday 17th October 2024, 18:00-19:30 (CEST)

Frailty has a significant impact on health and wellbeing, especially in older adults. Join our experts to understand the factors that contribute to the development of frailty and find out how to manage the condition and reduce the risk of disability, dependency, and mortality.
ADVANCED SEARCH
Log in
Top
Journal of General Internal Medicine

25-09-2024 | Biomarkers | Perspective

“My Biomarkers Are Fine, Thank You”: On the Biomarkerization of Modern Medicine

Author: Bjørn Hofmann, PhD

Published in: Journal of General Internal Medicine

Login to get access

Abstract

Biomarkers are becoming crucial in ever more medical tasks and are proposed to change medicine in profound ways. By biomarking ever more attributes of human life, they tend to blur the distinction between health and disease and come to characterize life as such. Not only do biomarkers strongly influence the professional conception of disease by pervading ever more diagnoses, but they also impact patients’ experience of illness. To manage how biomarkers influence patients, professionals, and societies, we urgently need to move from identifying potentially relevant biomarkers to determine their meaning and value to individuals, professionals, and public health.
Literature
1.
Grady D, Pollack A. Finding Risks, Not Answers. Expanding Array of Gene Tests In: The New York Times New York edn New York: The New York Times A. 2014;17.
2.
3.
4.
Wishart DS, Bartok B, Oler E, et al. MarkerDB: an online database of molecular biomarkers. Nucleic Acids Res. 2021;49(D1):D1259-D67.CrossRefPubMed
5.
6.
7.
8.
9.
10.
11.
Robb MA, McInnes PM, Califf RM. Biomarkers and surrogate endpoints: developing common terminology and definitions. Jama. 2016;315(11):1107-08.CrossRefPubMed
12.
Alzheimer’s Association Workgroup. Revised Criteria for Diagnosis and Staging of Alzheimer's Disease National Institute of Aging-Alzheimer’s Association, 2023.
13.
14.
Metzler I. Biomarkers and their consequences for the biomedical profession: a social science perspective. Per Med. 2010;7(4):407-20.CrossRefPubMed
15.
Hofmann B (2017) Technological Invention of Disease Encyclopedia of Creativity, Invention, Innovation and Entrepreneurship. New York, NY: Springer New York, 1–12.
16.
17.
18.
19.
Amin R, Dey BK, Alam F, et al. Cutting-edge approach for Alzheimer’s disease detection in the early stages: an overview. Int J Surg. 2023;109(3):582-83.CrossRefPubMedPubMedCentral
20.
Merino V, Garrido A. Digital Biomarkers for Early Detection of Cognitive Decline in Alzheimer's Disease. Arch Clin Psychiatry. 2023;50(6):182-189.
21.
Stites SD, Milne R, Karlawish J. Advances in Alzheimer's imaging are changing the experience of Alzheimer's disease. Alzheimers Dement (Amst). 2018;10:285-300.CrossRefPubMed
22.
23.
Undeland M, Malterud K. The fibromyalgia diagnosis: hardly helpful for the patients? A qualitative focus group study. Scand J Prim Health Care 2007;25:250-55.CrossRefPubMedPubMedCentral
24.
25.
26.
Jørgensen P, Langhammer A, Krokstad S, et al. Diagnostic labelling influences self-rated health. A prospective cohort study: the HUNT Study, Norway. Fam Pract. 2015;32(5):492-9
27.
28.
Bergen JP, Verbeek P-P. To-do is to be: Foucault, Levinas, and technologically mediated subjectivation. Philos Technol. 2021;34(2):325-48.CrossRef
29.
Welch HG, Schwartz L, Woloshin S. (2011) Overdiagnosed : making people sick in the pursuit of health. Boston, Mass.: Beacon Press
30.
31.
32.
Deeks JJ, Ashby D, Takwoingi Y, et al. Lessons to be learned from test evaluations during the COVID-19 pandemic: RSS Working Group’s Report on Diagnostic Tests. J R Stat Soc 2024;Series A: Statistics in Society:qnae053.
33.
Wallach JD, Yoon S, Doernberg H, et al. Associations between surrogate markers and clinical outcomes for nononcologic chronic disease treatments. JAMA. 2024;331(19):1646-54.
34.
35.
36.
Halim A. Biomarkers, Diagnostics and Precision Medicine in the Drug Industry: Critical Challenges, Limitations and Roadmaps for the Best Practices: Academic Press, 2019.
37.
Jain KK, Jain KK. Legal & Regulatory Aspects of Personalized Medicine. Textbook Personalized Med. Cham: Springer International Publishing; 2021:683-700.
38.
Bradley LA, Edwards IT. Evaluation of Genomic Applications in Practice and Prevention: Implementation and Evaluation of a Model Approach. Genomics Popul Health. 2005 2004:35.
39.
Horvath AR, Lord SJ, StJohn A, et al. From biomarkers to medical tests: the changing landscape of test evaluation. Clin Chim Acta. 2014;427:49-57.CrossRefPubMed
Metadata
Title
“My Biomarkers Are Fine, Thank You”: On the Biomarkerization of Modern Medicine
Author
Bjørn Hofmann, PhD
Publication date
25-09-2024
Publisher
Springer International Publishing
Published in
Journal of General Internal Medicine
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-024-09019-8

EASD 2024

‘Noninferior’ reduction of type 1 diabetes HbA1c by weekly insulin efsitora alfa

Weekly treatment with insulin efsitora is noninferior to daily insulin degludec for the reduction of HbA1c in adults with type 1 diabetes, show the findings of the QWINT-5 trial.

Read more

Weight loss with new obesity drug amycretin

Tirzepatide significantly reduces UACR in individuals with obesity and type 2 diabetes

Liraglutide reduces BMI for young children with obesity

» View more highlights on the EASD 2024 hub page

2024 ESC Congress

Noise pollution dangerous for heart health

Two studies underscore the adverse impact of noise pollution on the risk for and prognosis after myocardial infarction.

Read more

Post-TAVI follow up: deploying virtual assistants

Antihypertensives: more effective at morning or night?

Low Lp(a) levels unlikely to increase the risk of diabetes

» View more highlights on the 2024 ESC Congress hub page

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more
Image Credits